Literature DB >> 3081282

Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

J Chmielewska, B Wiman.   

Abstract

We describe efficient, accurate methods for specific determination of tissue plasminogen activator (t-PA, EC 3.4.21.31) and its "fast" inhibitor in plasma. In this coupled assay, a sample containing t-PA is incubated with plasminogen, a plasmin (EC 3.4.21.7) substrate of low Km and high Kcat, and fibrin as a stimulator. The inhibitor of t-PA is determined by incubating the sample with a known amount of t-PA in excess, then determining the residual t-PA. Both t-PA and t-PA inhibitor can be determined in many samples simultaneously within a few hours. These assays are modifications of procedures described by us (Clin Chim Acta 1983;127:279-88 and Thromb Res 1983;31:427-36). Their accuracy as assessed by analytical recovery of pure t-PA added to blood samples (91 +/- 4%) or of partly purified inhibitor added to plasma samples (102 +/- 10%) is satisfactory, as is their precision. For the t-PA assay the CV was 1.6% (within run) or 4.1% (between run). The corresponding values for the inhibitor assay were 4.5% (within run) or 8.4% (between run) if the inhibitor concentration exceeded 3 arb. units/mL.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081282

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  17 in total

1.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

2.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

3.  Distribution of plasminogen activator inhibitor (PAI-1) in tissues.

Authors:  A J Simpson; N A Booth; N R Moore; B Bennett
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

4.  The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

Authors:  T L Lindahl; P I Ohlsson; B Wiman
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

5.  Endothelial cell derived factors in relation to antibodies to SSA or SSB and to endothelial cells in Sjögren's syndrome.

Authors:  S Rantapää-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

6.  Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis.

Authors:  Ali A El Solh; Milapchand Bhora; Lilibeth Pineda; Alan Aquilina; Laurie Abbetessa; Eileen Berbary
Journal:  Intensive Care Med       Date:  2005-11-12       Impact factor: 17.440

7.  Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes.

Authors:  Denise A B Smith; Sampada S Vaidya; Jonathan A Kopechek; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2010-01       Impact factor: 2.998

8.  Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.

Authors:  J H Jansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions.

Authors:  J Chmielewska; M Rånby; B Wiman
Journal:  Biochem J       Date:  1988-04-15       Impact factor: 3.857

10.  The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase.

Authors:  Johan B Nilsson; Kurt Boman; Jan-Håkan Jansson; Torbjörn Nilsson; Ulf Näslund
Journal:  J Thromb Thrombolysis       Date:  2007-08-25       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.